Barcelona, October 5, 2022 – CanSino Biologics Inc. (“CanSinoBIO”) (SSE: 688185, HKEX: 06185) today announced that Dr. Jean-Denis Shu, Senior Vice President of CanSinoBIO, will be presenting clinical trial data for the Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) for Inhalation (trade name: Convidecia Air™) at the upcoming World Vaccine Congress (“WVC”) Europe to be held from October 11 to 14, 2022 in Barcelona, Spain. Dr Shu will be presenting data during a 15-minute session at 13.45 CET on Thursday 13 October (Clinical evaluation of Ad5 viral vector based Covid-19 vaccine immunization via inhaled delivery route). Dr. Shu will also be co-hosting a roundtable session titled “The Benefits of Mucosal Immunity”, with Dr. Pierre Morgon, Executive Vice President for Portfolio Strategy and Supranational Affairs of CanSinoBIO, at 11:00 CET on Wednesday 12 October.

These data will show that Convidecia Air™ induces a strong and lasting immune response^[1], with greater immunogenicity against the Omicron variant than recombinant protein or inactivated vaccines. The neutralizing antibody levels against the Omicron variant with Convidecia Air™ are also twice higher than those of the intramuscular version, Convidecia™. Convidecia Air™ received approval to be used as a booster in China in September 2022 and was approved for clinical trials in Malaysia in August 2022.

“This is an exciting breakthrough for our fight against COVID-19. Convidecia Air™ provides an added layer of mucosal immunity that can potentially block the transmission of virus variants. We are so proud of the teamwork that has led to the first-ever inhaled vaccine ready to be commercialized worldwide,” said Dr. Pierre Morgon, Executive Vice President for Portfolio Strategy and Supranational Affairs of CanSinoBIO. “We are delighted that, with the approval of Convidecia Air™ in China, and hopefully in other countries to come, we can help strengthen protection against the virus with this innovative vaccine option that is needle-free, painless and non-invasive.”

A peer-reviewed study^[2] published by The Lancet in July 2021 indicated that Convidecia Air™ is safe to use and can induce strong humoral, cellular and mucosal immunity with only one-fifth of the dosage of the intramuscular version of CanSinoBIO’s COVID-19 vaccine. The inhaled treatment can achieve triple protection as it triggers a mucosal immune response in addition to humoral and cellular immunity observed in people administered with intramuscular vaccines. Notably, mucosal immune response develops in the respiratory tract, where COVID-19 takes hold, and thus it can reduce virus carriage and prevent potential transmission to other individuals.

Both Convidecia™ and Convidecia Air™ can be stably stored and transported between 2°C to 8°C. The ease in transport, storage and delivery of Convidecia Air™ provides more advantages for countries that lack adequate infrastructure support to roll out vaccination programs, making Convidecia Air™ a more effective and efficient option as heterologous booster for quick and mass-scale protection.

Register for CanSinoBIOs WVC 2022 newsroom, containing exclusive press materials and the opportunity to ask questions and request 1:1 interviews with Dr. Pierre and Dr. Jean-Denis. For more information on the WVC 2022, please view https://www.terrapinn.com/conference/world-vaccine-congress-europe/index.stm.]

[1] Source: https://www.medrxiv.org/content/10.1101/2022.03.08.22271816v1

[2] Source: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00396-0/fulltext